Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein
- PMID: 15780866
- PMCID: PMC7111832
- DOI: 10.1016/j.virol.2005.01.042
Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein
Abstract
A secreted, glycosylated polypeptide containing amino acids 14 to 762 of the SARS coronavirus (SARS-CoV) spike protein and a polyhistidine tag was expressed in recombinant baculovirus-infected insect cells. Mice received the affinity-purified protein with either a saponin (QS21) or a Ribi (MPL + TDM) adjuvant subcutaneously and were challenged intranasally with SARS-CoV. Both regimens induced binding and neutralizing antibodies and protection against SARS-CoV intranasal infection. However, the best results were obtained with QS21 and protein, which provided the highest antibody as well as complete protection of the upper and lower respiratory tract.
Figures
Similar articles
-
Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.Vaccine. 2011 Sep 2;29(38):6606-13. doi: 10.1016/j.vaccine.2011.06.111. Epub 2011 Jul 14. Vaccine. 2011. PMID: 21762752 Free PMC article.
-
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9. doi: 10.1073/pnas.0403492101. Epub 2004 Jun 21. Proc Natl Acad Sci U S A. 2004. PMID: 15210961 Free PMC article.
-
Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.J Gen Virol. 2006 Mar;87(Pt 3):641-650. doi: 10.1099/vir.0.81579-0. J Gen Virol. 2006. PMID: 16476986
-
Vaccine design for severe acute respiratory syndrome coronavirus.Viral Immunol. 2005;18(2):327-32. doi: 10.1089/vim.2005.18.327. Viral Immunol. 2005. PMID: 16035944 Review.
-
SARS vaccine development.Emerg Infect Dis. 2005 Jul;11(7):1016-20. doi: 10.3201/1107.050219. Emerg Infect Dis. 2005. PMID: 16022774 Free PMC article. Review.
Cited by
-
Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.Vaccine. 2007 Apr 12;25(15):2832-8. doi: 10.1016/j.vaccine.2006.10.031. Epub 2006 Oct 30. Vaccine. 2007. PMID: 17092615 Free PMC article.
-
Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness.Vaccines (Basel). 2023 Aug 9;11(8):1347. doi: 10.3390/vaccines11081347. Vaccines (Basel). 2023. PMID: 37631915 Free PMC article. Review.
-
Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt.Antib Ther. 2021 Jun 25;4(3):135-143. doi: 10.1093/abt/tbab012. eCollection 2021 Jul. Antib Ther. 2021. PMID: 34286215 Free PMC article.
-
A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.Curr Top Med Chem. 2024;24(21):1883-1916. doi: 10.2174/0115680266296095240529114058. Curr Top Med Chem. 2024. PMID: 38859776 Review.
-
Exploring the possible use of saponin adjuvants in COVID-19 vaccine.Hum Vaccin Immunother. 2020 Dec 1;16(12):2944-2953. doi: 10.1080/21645515.2020.1833579. Epub 2020 Dec 9. Hum Vaccin Immunother. 2020. PMID: 33295829 Free PMC article. Review.
References
-
- Berry J.D., Jones S., Drebot M.A., Andonov A., Sabara M., Yuan X.Y., Weingartl H., Fernando L., Marszal P., Gren J., Nicolas B., Andonova M., Ranada F., Gubbins M.J., Ball T.B., Kitching P., Li Y., Kabani A., Plummer F. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J. Virol. Methods. 2004;120:87–96. - PMC - PubMed
-
- Bukreyev A., Lamirande E.W., Buchholz U.J., Vogel L.N., Elkins W.R., St. Claire M., Murphy B.R., Subbarao K., Collins P.L. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004;363:2122–2127. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous